Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Andrea Rottenfusser"'
Autor:
H. Eiter, Peter Dubsky, Günther G. Steger, Zsuzsanna Bago-Horvath, Matthias Preusser, Christoph C. Zielinski, Ursula Pluschnig, Florian Fitzal, C De Vries, Michael Knauer, Andrea Rottenfusser, Rupert Bartsch, Margaretha Rudas, Karin Dieckmann, Robert M. Mader, Anna S. Berghoff, Michael Gnant
Publikováno v:
British Journal of Cancer
Background: Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; in addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain metastases free survival (BM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a66eff91275d075ab61f0ebd5a623c6
http://europepmc.org/articles/PMC3273356
http://europepmc.org/articles/PMC3273356
Autor:
Anna S. Berghoff, Rupert Bartsch, Christoph C. Zielinski, Margaretha Rudas, Ursula Pluschnig, Günther G. Steger, Michael Gnant, Zsuzsanna Bago-Horvath, Robert M. Mader, Andrea Rottenfusser, C. DeVries, Peter Dubsky, Florian Fitzal, Karin Dieckmann
Publikováno v:
Cancer Research. 71:P4-17
BACKGROUND Brain metastases (BM) are frequently diagnosed in patients (pts) with Her2-positive metastatic breast cancer (BC); a rising incidence was also reported in triple-negative disease. We hypothesized that pts with triple-negative or Her2-posit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4322b98cf69eca7f1efdc228efe0054a
https://doi.org/10.1158/0008-5472.sabcs11-p4-17-05
https://doi.org/10.1158/0008-5472.sabcs11-p4-17-05
Autor:
Ursula Pluschnig, Zsuzsanna Bago-Horvath, Rupert Bartsch, Margaretha Rudas, Anna S. Berghoff, Michael Gnant, Peter Dubsky, Andrea Rottenfusser, Florian Fitzal, Karin Dieckmann, Robert M. Mader, C. DeVries, Christoph C. Zielinski, Günther G. Steger
Publikováno v:
British Journal of Cancer
Background: Trastuzumab-based therapy after diagnosis of brain metastases (BM) may improve survival due to prolonged systemic disease control. We investigated whether lapatinib may yield additional survival benefit. Methods: Eighty patients with BM f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64ec930298b08d53c115ed3727a3a753
https://doi.org/10.1038/bjc.2011.531
https://doi.org/10.1038/bjc.2011.531
Autor:
Georg Pfeiler, Mustafa Tukenmez, Guoping Ren, Guenther G. Steger, Alessa Heinrichs, Memduh Dursun, Qiqi Gao, Sidika Kurul, Omer Aran, Richard Greil, Anna S. Berghoff, Michael Hubalek, Hasan Karanlik, Michael Knauer, Bo Wang, Annika Waldmann, Robert M. Mader, Peyman Hadji, Telja Pursche, Jens Huober, Yulong Zheng, Florian Schuetz, Catharina De Vries, İlker Özgür, Gabriel Rinnerthaler, Cornelia Sparber, Christoph Domschke, Achim Rody, Michael Gnant, Dorothea Fischer, Simon P. Gampenrieder, Özgür Özyüncü, Elisabeth Bergen, Dilek Sahin, Matthias Kalder, Claudia Sattlberger, Zihan Wu, Beat Thürlimann, Rupert Bartsch, Margaretha Rudas, Serife Simsek, Matthias Preusser, M. Sinan Beksaç, Andrea Rottenfusser, Christian F. Singer, Christoph C. Zielinski, Flora Zagouri, Peter Dubsky, Kemal Beksac, Kristin Baumann, Florian Fitzal, Alisan Fathalizadeh, Marianne Hedderich, Derman Basaran, Constanze Banz-Jansen, Mert Turgal
Publikováno v:
Breast Care. 9:149-151
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec2619e07563a27e14d059562bf23523
https://doi.org/10.1159/000365856
https://doi.org/10.1159/000365856
Autor:
Karin Dieckmann, Katarzyna Elandt, Christine Marosi, Marco Hassler, Andrea Rottenfusser, Johann Lehrner, Petra Binder, Matthias Preusser
Publikováno v:
Journal of Neuro-Oncology. 97:109-115
Although their neurocognitive performance is one of the major concerns of patients with high-grade gliomas (HGG) and although neurocognitive deficits have been described to be associated with negative outcome, neurocognitive rehabilitation is usually
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4229a97d8d5c191793a0fa6cbd48da2d
https://doi.org/10.1007/s11060-009-0006-2
https://doi.org/10.1007/s11060-009-0006-2
Autor:
Ursula Pluschnig, Gabriela Altorjai, Catharina Wenzel, Christoph C. Zielinski, Richard Poetter, Karin Dieckmann, Andrea Rottenfusser, Robert M. Mader, Guenther G. Steger, Rupert Bartsch, Margaretha Rudas
Publikováno v:
Journal of Neuro-Oncology. 85:311-317
Background: Brain metastases are frequently encountered in Her2 positive advanced breast cancer. It is still not clear, if trastuzumab treatment should be continued following their diagnosis. In this analysis we evaluated if trastuzumab was able to i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30df00e74e6711f53a8efd39c2b8d5ad
https://doi.org/10.1007/s11060-007-9420-5
https://doi.org/10.1007/s11060-007-9420-5
Autor:
Friedrich Hofbauer, Michael Stierer, G. Luschin-Ebengreuth, Karin S. Kapp, Leonore Handl-Zeller, Susanne Taucher, G. Reiner, Michael Gnant, Christoph Tausch, Felix Sedlmayer, Karin Haider, B. Pakisch, Sabine Pöstlberger, Raimund Jakesz, Richard Pötter, Andrea Rottenfusser, W. Draxler, Werner Kwasny, Marianne Schmid, Josef Hammer
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 68:334-340
In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial.Between January 1996 and June 2004, the Austrian Breast and Colorectal Cancer Study Gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90fc3312af08b4085440508bb087e216
https://doi.org/10.1016/j.ijrobp.2006.12.045
https://doi.org/10.1016/j.ijrobp.2006.12.045
Autor:
Claudia Sattlberger, Michael Gnant, Rupert Bartsch, Margaretha Rudas, Elisabeth Bergen, Peter Dubsky, Catharina De Vries, Cornelia Sparber, Anna S. Berghoff, Matthias Preusser, Christoph C. Zielinski, Guenther G. Steger, Robert M. Mader, Florian Fitzal, Andrea Rottenfusser, Flora Zagouri
Background: This retrospective analysis was planned as a direct comparison of taxanes plus trastuzumab to the less toxic combination of oral vinorelbine (OV) plus trastuzumab as a first-line therapy for metastatic HER2-positive breast cancer. Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a67fb3f3a07def6412ac548450d8b56
https://europepmc.org/articles/PMC4322687/
https://europepmc.org/articles/PMC4322687/
Publikováno v:
Strahlentherapie und Onkologie. 183:11-13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d0ae0b3f7890d308f63f2d6e101135c
https://doi.org/10.1007/s00066-007-2005-6
https://doi.org/10.1007/s00066-007-2005-6
Autor:
Peter Dubsky, Ursula Pluschnig, Florian Fitzal, Guenther G. Steger, Anna S. Berghoff, Michael Gnant, Robert M. Mader, C. DeVries, Christoph C. Zielinski, Andrea Rottenfusser, Zsuzsanna Bago-Horvath, Rupert Bartsch, Margaretha Rudas
Publikováno v:
European journal of cancer (Oxford, England : 1990). 48(13)
Background Endocrine therapy is the preferred treatment for hormone-receptor (HR) positive metastatic breast cancer. In premenopausal patients, ovarian function suppression with goserelin in combination with anastrozole yielded promising results in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b55565664f3039172f64d8884ce0649f
https://pubmed.ncbi.nlm.nih.gov/22459763
https://pubmed.ncbi.nlm.nih.gov/22459763